Not available
Quote | Verona Pharma plc (NASDAQ:VRNA)
Last: | $15.46 |
---|---|
Change Percent: | 0.58% |
Open: | $15.42 |
Close: | $15.46 |
High: | $15.51 |
Low: | $14.86 |
Volume: | 1,052,446 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Verona Pharma plc (NASDAQ:VRNA)
2024-06-30 09:00:00 ET Summary VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for ...
2024-06-27 07:00:04 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $36.00 for VRNA on 2024-06-27 06:09:00. The adjusted price target was set to $36.00. At the time of the announcement, VRNA was trading at $14.69. The overall price target consensus is...
Message Board Posts | Verona Pharma plc (NASDAQ:VRNA)
Subject | By | Source | When |
---|---|---|---|
https://seekingalpha.com/article/4594258-verona-pharma-ensifentrine-vs-dupixent- | Amatuer17 | investorshub | 04/16/2023 11:57:08 PM |
Great news today AH - this little pharm | 4Godnwv | investorshub | 02/02/2023 12:25:44 AM |
25.77 | TheFinalCD | investorshub | 12/30/2022 8:11:15 PM |
COPD is a crowded place - not sure | Amatuer17 | investorshub | 12/30/2022 6:23:41 PM |
Very few sure bets on Nasdaq. | Laster | investorshub | 12/30/2022 5:18:10 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-27 07:00:04 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $36.00 for VRNA on 2024-06-27 06:09:00. The adjusted price target was set to $36.00. At the time of the announcement, VRNA was trading at $14.69. The overall price target consensus is...
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIG...
2024-06-15 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...